Clinical Trials
716 trialsORCHID
Fudan University
GRECCAR12
University Hospital, Bordeaux
NOAHS-ARC
Servicio de Salud Metropolitano Sur Oriente
Predicting Response to Capecitabine in Women With Metastatic Breast Cancer
Centre Antoine Lacassagne
Gemcitabine, Capecitabine, and Erlotinib in Treating Patients With Advanced Pancreatic Cancer
Centre Antoine Lacassagne
T-DXd_HER2Low
National Cancer Center Hospital East
Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer
Montefiore Medical Center
Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
A Study of Trastuzumab in Combination With Capecitabine and Cisplatin in Patients With Tissue HER2- But Serum HER2+ AGC
Asan Medical Center
COLOCROSS
Centre Oscar Lambret
KEYNOTE-585
Merck Sharp & Dohme LLC
KEYNOTE-585
Merck Sharp & Dohme LLC
MECCA
Sun Yat-sen University
DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
Daiichi Sankyo
KEYNOTE-859
Merck Sharp & Dohme LLC
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery
National Cancer Institute (NCI)
Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma
Case Comprehensive Cancer Center
HKI-272 for HER2-Positive Breast Cancer and Brain Metastases
Dana-Farber Cancer Institute
GRECCAR8
Hospices Civils de Lyon
MK-3475-811
Merck Sharp & Dohme LLC
Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer
National Cancer Institute (NCI)
LEAP-009
Merck Sharp & Dohme LLC
Window of Opportunity Study in Colorectal Cancer
National Cancer Centre, Singapore
IMpassion132
Hoffmann-La Roche
CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer
Dana-Farber Cancer Institute
The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC
National Cancer Centre, Singapore
A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy
Jiangsu HengRui Medicine Co., Ltd.
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Jazz Pharmaceuticals
PRECIOUS
Japan Breast Cancer Research Group
ACE
Oslo University Hospital
Efficacy and Safety of Triweekly Cetuximab in Combination With Capecitabine as First-line Maintenance Treatment for KRAS/BRAF Wild-type Metastatic Colorectal Cancer
Sun Yat-sen University
CinClare
Fudan University
Capecitabine as Maintenance Therapy vs Observation in Early-stage Triple-negative Breast Cancer
Beni-Suef University
Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors
BeiGene
Modified SCRT Followed by Tislelizumab Plus CAPOX for Locally Advanced Rectal Cancer
Fujian Cancer Hospital
KEYVIBE-005
Merck Sharp & Dohme LLC
LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib
Novartis
CheckMate649
Bristol-Myers Squibb
INNOVATION
European Organisation for Research and Treatment of Cancer - EORTC
A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
BeiGene
TALENT
The First Affiliated Hospital with Nanjing Medical University
TAC Versus TCX as Adjuvant Treatment for High-risk Her2-Negative Breast Cancer
Peking Union Medical College Hospital
FAST
Astellas Pharma Inc
A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors
Bristol-Myers Squibb
Néofirinox
UNICANCER
Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer
Imugene Limited
AIO-KRK-0114
Ludwig-Maximilians - University of Munich
Pembrolizumab, Capecitabine, and Bevacizumab for Treating Colorectal Cancer
University of California, San Francisco
ACO/ARO/AIO-21
Goethe University